GSK Sees Big Opportunity In OTC Diet Aids: Xenical Switch NDA Filed
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline filed an Rx-to-OTC switch application for Xenical (orlistat 60 mg) in June, the firm announced July 28
You may also be interested in...
Short-Term Xenical Treatment Benefits “Difficult To Define,” FDA Says
Efficacy concerns surrounding GlaxoSmithKline's Xenical (orlistat) may prove to be a bigger hurdle to overcome than safety or self-selection issues as the firm pursues an Rx-to-OTC switch of the drug
Xenical Short-Term Switch Odds Slimmer Than Long-Term – Experts
Xenical's long-term prospect for switch appears promising, but its chances of being recommended for OTC sale by an upcoming advisory panel are slim, some switch experts say
Xenical Study Supports Proposed Nonprescription Dose, Glaxo Says
The "behavior modification" effect ofXenical adverse events could help allay concerns that OTC availability would lead to people using orlistat without making appropriate adjustments to their diets, according to the principal investigator of a study on the drug